Who has Zenas partnered with for thyroid eye disease programs ... results from pivotal Phase 3 Trial in Immunoglobulin G4-Related Disease (INDIGO) expected year-end 2025- - Enrollment of Phase ...

Our thyroid ... disease that leads to a generalized overactivity of the entire thyroid gland. It is the most common cause of hyperthyroidism in the U.S. Graves’ disease is the only kind of ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

KOLOA, Hawaii — Effective management of thyroid eye disease requires a focus on mitigating ... at an increased risk for medical and implant-related complications after total shoulder ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations were $5.04. Operator: My name is Julienne, and I will be your conference ...

To protect your eye health and support your vision, these are 10 simple things you can do every day for your eyes.

Our thyroid produces two ... in the U.S. Graves’ disease is the only kind of hyperthyroidism that can be associated with inflammation of the eyes, swelling of tissues around the eyes and bulging ...

Topline results were announced from a phase 2/3 trial evaluating linsitinib for the treatment of active, moderate to severe thyroid eye disease (TED ... (10.3%), and muscle spasms (10.3%). No ...

Valeo Financial Advisors LLC bought a new stake in argenx SE (NASDAQ:ARGX – Free Report) during the 4th quarter, according to ...

Zenas Founder and Chief Executive Officer, Lonnie Moulder highlighted the company’s progress across various goals in 2024, ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.